

# What did we achieve?

We delivered a cohesive, multi-partner system to facilitate development of the entire precision medicine delivery pipeline and have achieved the following milestones.

**12x**

Turned a \$24 M investment into \$294 M in additional research funding

**>140**

143 new STEM jobs across the Westmead and Randwick precincts

**20**

Facilitated 20 R&D IPs and commercial collaborations

**450**

Collaborations with over 450 national and international organisations

**>150**

Over 150 publications adding to precision medicine knowledge

**20**

Over 20 clinical trials pharma and investigator led

**320**

Over 320 research projects

**1000s**


1000s of children and families supported



Facilitated exclusive national access to **paediatric gene therapy clinical trials**. Successful participation has led to the Sydney Children's Hospital becoming the first Australian site accredited to deliver approved gene therapies to Australian patients.




Funded support to roll-out a molecular test for spinal muscular atrophy as part of **newborn screening** in NSW and the ACT, leading to its inclusion on the newborn screening program nationally with access to a novel new gene therapy, Zolgensma®, listed on the Pharmaceutical Benefits Scheme.



Funding support for the establishment of the Children's Medical Research Institute's **Vector and Genome Engineering facility** and the **Translational Vectorology Research Unit**, along with the **Stem Cell and Organoid Facility**.



Data analysis and psychosocial support for the **Zero Childhood Cancer Program**, which enabled children with high-risk cancer to receive personalised treatment recommendations.



Breakthroughs in **ocular cell therapy** – a funded project, using organoids (mini-organs grown from a patient's own cells) to test novel therapy for blinding genetic eye disease, has enabled patients to walk without canes for the first time.



Initiated more than **20 clinical trials** including facilitating multiple **early-phase clinical trials** and the establishment of several **pharmaceutically sponsored clinical trials** in advanced therapeutics, providing unprecedented access to novel therapies for Australian children.



More than **320 research projects** undertaken. Luminesce Alliance has continued to share its knowledge, insights and findings with **over 150 publications** and **over 195 presentations** locally, nationally and internationally.